The proceeds from the financing will be used to advance Zag Bio's lead program into the clinic as a tolerogenic therapy to prevent or delay the onset of Type 1 diabetes.

Company Information

Company Status

Private & Independent

Industry

Life Sciences

Mailing Address

Undisclosed
Cambridge, MA Undisclosed
USA

Phone

Undisclosed

Website

www.zagbio.com

Email Address

Not Recorded

Overview

Zag Bio� has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body's natural process for training immune cells to recognize and tolerate self, halting or preventing autoimmune attacks on the body's own tissues.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jason Cole

Browse more venture capital transactions:

Prev: 10/28/2025: Fireworks AI venture capital transaction
Next: 10/28/2025: Frontline Wildfire Defense venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary